Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IPA ImmunoPrecise Antibodies	$1.11	$0.62	$0.27 ▼ $1.16	$50.80M	0.12	2.51 million shs	1.09 million shs
OGI Organigram Global	$1.35 -3.6%	$1.27	$0.85 ▼ $2.08	$187.51M	1.37	658,979 shs	540,412 shs
TIL Instil Bio	$22.97 +3.6%	$22.43	$9.62 ▼ $92.00	$145.41M	2.27	184,367 shs	292,777 shs
TLSA Tiziana Life Sciences	$1.60 -10.1%	$1.45	$0.63 ▼ $1.91	$207.99M	-0.09	474,598 shs	484,154 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IPA ImmunoPrecise Antibodies	0.00%	+10.45%	+98.85%	+183.16%	+10.45%
OGI Organigram Global	-3.57%	+4.65%	0.00%	+31.07%	-11.48%
TIL Instil Bio	+3.61%	-17.08%	-14.13%	+27.05%	+136.80%
TLSA Tiziana Life Sciences	-10.11%	+2.56%	+15.11%	+42.86%	+72.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IPA ImmunoPrecise Antibodies	2.3347 of 5 stars	3.5	3.0	2.7	0.0	0.6
OGI Organigram Global	1.363 of 5 stars	0.0	1.0	3.8	0.0	2.5
TIL Instil Bio	3.2914 of 5 stars	3.5	2.0	2.5	3.3	1.3
TLSA Tiziana Life Sciences	1.4043 of 5 stars	0.0	5.0	3.3	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IPA ImmunoPrecise Antibodies	3.00	Buy	$4.00	260.36% Upside
OGI Organigram Global	3.00	Buy	N/A	N/A
TIL Instil Bio	3.00	Buy	$119.00	418.07% Upside
TLSA Tiziana Life Sciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest IPA, TLSA, TIL, and OGI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
6/2/2025	TIL Instil Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/22/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$110.00 ➝ $105.00
4/11/2025	IPA ImmunoPrecise Antibodies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/1/2025	IPA ImmunoPrecise Antibodies	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Speculative Buy ➝ Speculative Buy	$3.00 ➝ $3.00
3/31/2025	IPA ImmunoPrecise Antibodies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $5.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IPA ImmunoPrecise Antibodies	$18.16M	2.80	N/A	N/A	$0.93 per share	1.19
OGI Organigram Global	$117.47M	1.54	N/A	N/A	$2.07 per share	0.65
TIL Instil Bio	N/A	N/A	N/A	N/A	$25.96 per share	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	$0.04 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IPA ImmunoPrecise Antibodies	-$20.13M	-$1.16	N/A	N/A	N/A	-190.76%	-88.87%	-49.26%	7/3/2025 (Estimated)
OGI Organigram Global	-$33.39M	$0.10	13.50	N/A	N/A	8.05%	-5.93%	-4.39%	8/12/2025 (Estimated)
TIL Instil Bio	-$74.14M	-$11.97	N/A	N/A	N/A	N/A	-45.52%	-29.23%	8/12/2025 (Estimated)
TLSA Tiziana Life Sciences	-$11.86M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/5/2025 (Estimated)

Latest IPA, TLSA, TIL, and OGI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/13/2025	Q1 2025	TIL Instil Bio	-$2.02	-$4.32	-$2.30	-$4.32	N/A	N/A
3/28/2025	Q3 2025	IPA ImmunoPrecise Antibodies	-$0.06	-$0.06	N/A	-$0.46	$6.59 million	$4.23 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IPA ImmunoPrecise Antibodies	N/A	N/A	N/A	N/A	N/A
OGI Organigram Global	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IPA ImmunoPrecise Antibodies	0.45	2.32	2.11
OGI Organigram Global	N/A	3.42	1.90
TIL Instil Bio	0.58	30.33	30.33
TLSA Tiziana Life Sciences	N/A	1.02	1.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IPA ImmunoPrecise Antibodies	6.70%
OGI Organigram Global	34.63%
TIL Instil Bio	60.56%
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
IPA ImmunoPrecise Antibodies	6.83%
OGI Organigram Global	0.09%
TIL Instil Bio	47.20%
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IPA ImmunoPrecise Antibodies	80	45.76 million	42.64 million	Not Optionable
OGI Organigram Global	860	133.94 million	133.82 million	Optionable
TIL Instil Bio	410	6.56 million	3.46 million	No Data
TLSA Tiziana Life Sciences	8	116.85 million	70.32 million	Optionable

IPA, TLSA, TIL, and OGI Headlines

Recent News About These Companies

Tiziana Life Sciences (NASDAQ:TLSA) Trading 5.8% Higher - Time to Buy?

June 17, 2025 | marketbeat.com

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting

June 13, 2025 | seekingalpha.com

Tiziana Life Sciences expands Phase 2 MS trial to fifth site, commences patient dosing

June 13, 2025 | proactiveinvestors.com

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

June 13, 2025 | globenewswire.com

Tiziana Life Sciences to Present at the Bio International Convention

June 13, 2025 | globenewswire.com

Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 15.3% - Still a Buy?

May 28, 2025 | marketbeat.com

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

May 23, 2025 | finance.yahoo.com

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 23, 2025 | globenewswire.com

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 15, 2025 | finance.yahoo.com

Tiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study shows

May 15, 2025 | proactiveinvestors.com

Tiziana Life Sciences reports purchase of shares by chairman

May 12, 2025 | msn.com

Tiziana Life Sciences Announces Purchase of Shares by Chairman

May 12, 2025 | globenewswire.com

Tiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumab

May 9, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 9, 2025 | globenewswire.com

Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study

May 8, 2025 | pmlive.comP

Tiziana shares surge 21% on promising multiple sclerosis data

May 6, 2025 | proactiveinvestors.com

Tiziana reports encouraging results for nasal MS drug in early study

May 6, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

May 6, 2025 | globenewswire.com

Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025

April 30, 2025 | insidermonkey.com

Tiziana Life Sciences announces patient dosing in Phase 2 MS trial at University of Massachusetts

April 23, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

April 23, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Among the Market’s Most Shorted: 2 Firms With +40% Short Interest
By Leo Miller | June 3, 2025
View Among the Market’s Most Shorted: 2 Firms With +40% Short Interest
3 Stocks Getting Rare Double Upgrades From Analysts
By Chris Markoch | June 6, 2025
View 3 Stocks Getting Rare Double Upgrades From Analysts
AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
By Thomas Hughes | June 16, 2025
View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
Breakout Momentum Plays You May Not Know About
By Nathan Reiff | June 6, 2025
View Breakout Momentum Plays You May Not Know About
SoundHound’s AI Growth Story Is Just Getting Started
By Gabriel Osorio-Mazilli | June 16, 2025
View SoundHound’s AI Growth Story Is Just Getting Started

IPA, TLSA, TIL, and OGI Company Descriptions

ImmunoPrecise Antibodies NASDAQ:IPA

$1.11 0.00 (0.00%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.10 -0.02 (-1.35%)

As of 06/27/2025 07:56 PM Eastern

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

Organigram Global NASDAQ:OGI

$1.35 -0.05 (-3.57%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.38 +0.02 (+1.85%)

As of 06/27/2025 07:37 PM Eastern

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.

Instil Bio NASDAQ:TIL

$22.97 +0.80 (+3.61%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$22.88 -0.09 (-0.41%)

As of 06/27/2025 07:23 PM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Tiziana Life Sciences NASDAQ:TLSA

$1.60 -0.18 (-10.11%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.61 +0.01 (+0.63%)

As of 06/27/2025 06:13 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time